Nanobiotix And HealthCare Royalty Ink 71M Non-Dilutive Financing Agreement To Support JNJ-1900 (NBTXR3) Development And Long-Term Growth
Benzinga Newsdesk 1 year ago
News
$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial
- $71 million in funding would extend Nanobiotix cash visibility into early 2028
- Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancer
- Financing establishes financial foundation toward self-sustainability and the advancement of next wave nanotherapeutic platforms for long-term growth
- HealthCare Royalty (HCRx) will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3) payable to Nanobiotix under its global licensing agreement